2013 GIBH

2010-2013 Product Development/Portfolio Manager, R&D, Biotherapeutics,Molecular Devices

2009-2010 Senior Scientist, R&D, Drug Discovery,Leica

2008-2009 Non-Clinical Research Fellow ,Royal Hallamshire Hospital

2005-2008 Doctoral Research Student, PhD,Medical School, Sheffield

2002-2005 Bachelor's Degree, Bsci, Biochemistry,University of Sheffield

2000-2002 A-level, Barnsley College

C ell line engineering with instrumentation development for Biotherapeutics application in an automated manner under GMP for clinical use

hiPSCs application development for HCS / HTS drug screening and clinical application

Cell Signalling in Innate Immunity and Inflammation for cardiovascular application

2012 -Co-Investigator/Applicant , BBSRC,(grant No. BB/J009687) industryapplication grant:Defining TILRR regulation of distinct IL-1RI responses using systems biology –￡1,2M

2010 - R&D Exceptional Science Award,

US Patent No. 11183497.4-2401 & 7-3699: in ClonePixII^TM

ZHANG X, MONTAGUT PINO G, SHEPHARD F, KISS-TOTH E and QWARNSTROM EE, 2012. Distinct control of MyD88-dependent and AKT-regulated responses by the IL-1R1 co-receptor, TILRR. Journal of Biological Chemistry. 287(15), 12348-52 Cover of Journal issue April 6th, 2012

ZHANG, XIAO, SHEPHARD, FREYA, KIM, HONG B, PALMER, IAN R, MCHARG, SELINA, FOWLER, GREGORY J S, O'NEILL, LUKE A J, KISS-TOTH, ENDRE and QWARNSTROM, EVA E, 2010. TILRR, a novel IL-1RI co-receptor, potentiates MyD88 recruitment to control Ras-dependent amplification of NF-kappaB. The Journal of biological chemistry. 285(10), 7222-32

Monica Neilan,Xiao Zhang, Sheila Francis, Eva E Qwarnstrom, 2010.BAS/BSCR51 Control of vascular cell inflammatory responses through TILRR, an interleukin 1 co-receptor. Heart. 10; 96(17):e27.

M Neilan,X Zhang, T Steiner, J Boyle, S Francis, D Haskard, E Qwarnstrom, 2012. TILRR Functional Mutants Selectively Inhibit Inflammatory and Anti-Apoptotic Responses. Heart. 12; 98(10):e6